ClinicalTrials.gg

Program

VSJ-110

A development code.

Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic, led by Vanda Pharmaceuticals.

Furthest: phase 2, since Nov 4, 20203 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals32 open or runningphase 2since Nov 4, 2020Nov 4, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2020First study: phase 2 study in Conjunctivitis, AllergicFirst studyNCT04622345 · 47 enrolled · United States
  2. Feb 26, 2024Phase 2 study in Dry Eye SyndromesNCT06296966 · 40 planned · United States
  3. Sep 10, 2025Phase 2 study in Dry Eye SyndromesNCT07179055 · 160 planned · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07179055Dry Eye Syndromes · United States2RecruitingSep 2026160
NCT06296966Dry Eye Syndromes · United States2RecruitingJul 202440
NCT04622345Conjunctivitis, Allergic · United States2CompletedMay 22, 202147

How it is read

Names in the registry

  • “VSJ-110”, 3 entries

Codes read as this program: VSJ110.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
VSJ-110 (Vanda Pharmaceuticals): development program | ClinicalTrials.gg